Last year saw a sharp acceleration in new models of value-based care launched by the Centers for Medicare and Medicaid ...

Care payment models CMS introduced in 2025 include six new initiatives targeting drug pricing, chronic disease, and specialty care payments.

CMS has been trying to scale value-based care for decades with mixed results — but the agency’s newly announced ACCESS model could represent a more meaningful step toward aligning payment with ...

CMS is developing the ACCESS Model, a new national program that will pay Medicare Part B–enrolled organizations based on chronic-condition outcomes, care coordination and social-needs integration, ...

The Centers for Medicare and Medicaid Services is terminating the Medicare Advantage Value-Based Insurance Design (VBID) model at the end of 2025 due to what it called the model's "substantial and ...

The final rule implementing the Increasing Organ Transplant Access (IOTA) payment model has been released by the Centers for Medicare & Medicaid Services (CMS). Kidney transplant hospitals face new ...

For decades, chronic disease management in Medicare has been hampered by a fee-for-service payment system that rewards volume and activity rather than true clinical improvement. This model created ...

The Trump administration has unveiled yet another new payment model, this one focused on the cost of GLP-1 therapies. The Centers for Medicare & Medicaid Services (CMS) on Tuesday announced the Better ...

Trump's executive order has led to the removal of health equity plans from the CMS's Enhancing Oncology Model (EOM). The EOM, successor to the Oncology Care Model, initially focused on health equity ...

McKesson's QCDR status allows direct data submission to CMS via iKnowMed EHR, enhancing oncology practice efficiency. Practice Insights supports reporting of nine oncology-specific QCDR measures, ...

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in select other countries with participating pharmaceutical manufacturers. Under ...